Opdivo and Yervoy for metastatic uveal melanoma – pro
While these two drugs are appropriate for skin melanoma, we are dealing with uveal melanoma, a clinically differently behaving disease, one that does not respond as well as melanoma to drug therapy and is not generally responsive to immunotherapy. Namikawa recently showed 1 response in 20 patients.A retrospective series of 8 patients showed two of the patients had a partial response, while four others had stable disease. Two other patients experienced disease progression. There is as of now insufficient literature support for ipilimumab and nivolumab for metastatic uveal melanoma.
Meredith Pelster, Stephen K. Gruschkus, Roland Bassett, Dan S. Gombos, Michael Shephard, Liberty Posada, …Phase II study of ipilimumab and nivolumab (ipi/nivo) in metastatic uveal melanoma (UM). Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019) 9522-9522.
Yang J, Manson DK, Marr BP, Carvajal RD. Treatment of uveal melanoma: where are we now?. Ther Adv Med Oncol. 2018;10:1758834018757175.
Vidhya Karivedu et al, Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience. Case Reports in Oncological Medicine
Volume 2019, Article ID 3560640, 8 pages
Namikawa K et al, Nivolumab for patients with metastatic uveal melanoma previously untreated with ipilimumab: a single-institution retrospective study.Melanoma Res. 2019 May 14.